MA-GRANDSTREAM-NETWORKS
Enreach, the fast-growing European unified communications group, has announced that multiple IP phones from Grandstream have been certified for use on its Unified Communications as a Service (UCaaS) platform, ISTRA by Enreach. Through Enreach for Service Providers , partners and their customers have immediate access to portable and video phones from Grandstream, plus carrier-grade devices designed for mass-deployment.
Bertrand Pourcelot, Managing Director at Enreach for Service Providers, said: “Grandstream’s name has become synonymous with IP phones that combine superior quality and ease-of-use, with options to suit a wide variety of budgets and requirements. Grandstream is a good fit for our portfolio of supporting products for the ISTRA by Enreach UCaaS platform, which is already used by approximately one million users via over 100 service providers in 20-plus countries.”
Grandstream IP phones certified for ISTRA by Enreach
Highlights of the ISTRA-certified range include Grandstream’s GXV3300 series of advanced IP video phones for Android, bringing multimedia AV communications to the desktop, with tablet-style functionality and web access.
For greater mobility in the workplace, the cordless WP810 and WP820 are portable WiFi IP phones, providing robust design and comprehensive features. As well as office or home-working environments, these phones are ideal for retail, logistics, medical, security and other vertical markets where portability is a benefit.
When large volumes of handsets are needed, the GRP2600 series of Carrier-Grade IP phones deliver powerful performance, simplicity of use and easy deployment. As well as supporting basic communications, these devices include next generation features for high-end users.
About ISTRA by Enreach
The ISTRA cloud based UCaaS platform is already deployed by over 100 service providers in more than 20 countries with approximately one million users. It is also the foundation for Enreach’s future-facing platform strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader.
Enreach for Service Providers
Based in Sophia-Antipolis, France, Enreach for Service Providers (previously known as Centile Telecom Applications) is a European leader in the development of Cloud PBX and unified communications platforms for operators and integrators. As well as supporting Enreach for Service Providers own service provider customers, ISTRA by Enreach UCaaS platform is the foundation for Enreach’s future-facing strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader. https://enreach.com/en/for-service-providers
About Enreach
Enreach is the parent company of various labels such as Voiceworks, Swyx, Eazit, i4IP, ipnordic, M Mobility, HeroBase, Network Telecom, Botsquad and masvoz. Enreach provides collaboration technology and telecoms services via their reselling and service providing partners or direct brands that are transformative for SMEs and the people that work with them. All brands contribute to intelligent, integrated IT and communication solutions that ensure optimal communication and workflow between organisations. Enreach’s mission is to give businesses access to the best communication and collaboration tools with an easy, user-centric interface built around their specific needs and systems. The group’s products put powerful features in reach of every business, no matter the industry or size, so their employees can focus on getting amazing things done. Enreach is active in the core markets Germany, the Netherlands, Denmark, UK, Spain and France with activities in 25 countries and 950 employees. https://enreach.com/
About Grandstream
Grandstream Networks, Inc. has been connecting the world since 2002 with SIP Unified Communications products and solutions that allow businesses to be more productive than ever before. Our award-winning solutions serve the small and medium business and enterprises markets and have been recognized throughout the world for their quality, reliability and innovation. Grandstream solutions lower communication costs increase security protection and enhance productivity. Their open standard SIP-based products offer broad interoperability throughout the industry, along with unrivaled features and flexibility. Visit www.grandstream.com for more information or connect with us on Facebook , LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005422/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom